| BackgroundsBreast cancer is the most common malignant tumor in women.About 1.7million new cases of breast cancer occur worldwide each year,and about 700,000women die from the disease.In recent years,the incidence rate of breast cancer in China has been increasing by 3%year by year.Triple negative breast cancer(TNBC)is defined as estrogen receptor(ER),progesterone receptor(PR)and human epidermal growth factor 2(Her-2)negative breast cancer.It accounts for 15%of all breast cancers.The detection and classification of ER,PR,and HER2 status are used to determine the likelihood of response to endocrine and HER2-directed therapy,respectively,rather than to specifically identify the"three-negative"phenotype.As a result,the thresholds for ER,PR,and HER2 used to describe TNBC have varied over the past decade.Most studies now use current guidelines from the American Society of Clinical Oncology and the College of American Pathologists to determine ER,PR,and HER2 negative:ER and PR with immunohistochemical chemistry(IHC)nuclear staining of less than 1%,and HER2 with IHC staining of 0 to 1+;if IHC shows 2+or can not be determined,fluorescence in situ hybridization(fluorescence in situ hybridization,FISH)less than 2.0 is negative.It occurs mostly in young women and is more common in black women.Triple negative breast cancer has its unique clinical and molecular features and usually presents with a higher pathological grade.Compared with other breast cancer subtypes,triple negative breast cancer cells have poor differentiation,high rate of recurrence and metastasis,rapid progress and poor prognosis.The 5-year survival rate is generally less than 80%.Chemotherapy is the primary treatment for this type of breast cancer,which is not sensitive to endocrine therapy or HER-2-positive Trastuzumab.Anthracycline and(or)taxanes have been used in the early chemotherapy of TNBC,so it is necessary to study the chemotherapy regimen of advanced triple negative breast cancer.ObjectiveIn order to provide better treatment for advanced triple negative breast cancer,the clinical efficacy and side effects of NP regimen and GP regimen in 54 patients with advanced triple negative breast cancer were analyzed retrospectively.MethodsA total of 54 female patients with advanced triple negative breast cancer were enrolled from August 2015 to August 2018 in the Department of Breast Surgery of the First Affiliated Hospital of Zhengzhou University,29 of whom were treated with Vinorelbine plus Cisplatin(NP)regimen methods:Vinorelbine 25mg/m~2,D1,D8,Cisplatin 25mg/m~2,D1-3.21 days is a cycle.A total of 25 patients were treated with the combination of Gissi and Cisplatin.GP regimen methods:Gissi 1000 mg/m~2,D1,D8,Cisplatin 25mg/m~2,D1-3.21 days as a cycle.Efficacy and side effects were evaluated after 2 cycles.According to the criterion of response to solid tumor(RECIST1.0),the therapeutic effect was divided into complete response(CR),partial response(PR),stable disease(SD)and progressive disease(PD).The effective rate was RR=(CR+PR)%,and the tumor control rate was(CR+PR+SD)%.The evaluation of adverse reactions during chemotherapy was classified according to CTCAE version 5.0.The data were analyzed by SPSS20.0 statistical software,the clinical data were described by percentage,qualitative data were chi-square test,and p<0.05 was statistically significant.Results1.In NP regimen group,CR was 2 cases(6.9%),PR was 8 cases(27.6%),SD was 13 cases(44.8%),PD was 6 cases(20.7%),effective rate was 34.5%,tumor control was rate 79.3%;in GP regimen group,CR was 2 cases(8.0%),PR was 7cases(28.0%),SD was 11 cases(44.0%),PD was 5 cases(20.0%),effective rate was 36.0%,tumor control rate was 80.0%.2.There was no significant difference in clinical efficacy and tumor control rate between the two chemotherapy regimens(p>0.05).3.There was no significant difference in the adverse reactions between the two groups(p>0.05).ConclusionNP regimen and GP regimen are the most commonly used chemotherapy regimens for advanced triple negative breast cancer.The two regimens have similar efficacy,controllable adverse reactions and good patient tolerance.Both regimens can be used as first-line treatment for advanced triple-negative breast cancer. |
PDF Full Text Request